drugset / Trial / NCT00153088
INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this study is to compare the preventive effect of Telmisartan(Micardis) versus placebo control on the transition to overt nephropathy in patients with diabetic nephropathy manifesting microalbuminuria associated with type II diabetes, and to evaluate the efficacy and safety of Telmisart (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) for diabetic nephropathy patients.
Timeline
- Start
- 2003-01
- Primary completion
- 2005-11
- Completion
- 2005-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telmisartan | Other / unclassified | 40 mg | — |
| Subject | Telmisartan | Other / unclassified | 80 mg | — |